Cargando…

Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer

PURPOSE: Inflammatory biomarkers and clinical pathological factors have been reported to predict survival of patients with non-small cell lung cancer (NSCLC). The goal of this study was to identify risk factors for early recurrence in patients with pIIIA-N2 NSCLC who had undergone radial resection....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Qiongjie, Du, Xuedan, Fang, Zhen, Mao, Xiaolu, Wu, Jinting, Wang, Bin, Li, Wenfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608410/ https://www.ncbi.nlm.nih.gov/pubmed/34819754 http://dx.doi.org/10.2147/CMAR.S337830

Ejemplares similares

Reappraisal of the role of postoperative radiation therapy in patients with pIIIa-N2 non-small cell lung cancer: A propensity score matching analysis
por: Cao, Qinchen, et al.
Publicado: (2015)

The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis
por: Liu, Tingting, et al.
Publicado: (2019)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
por: Hui, Zhouguang, et al.
Publicado: (2021)

Effect of Conformational Diversity on the Bioactivity of µ-Conotoxin PIIIA Disulfide Isomers
por: Paul George, Ajay Abisheck, et al.
Publicado: (2019)

Construction and Verification of a Hypoxia-Related 4-lncRNA Model for Prediction of Breast Cancer
por: Zhao, Ye, et al.
Publicado: (2021)

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
por: Montemuiño Muñiz, Sara, et al.
Publicado: (2021)

Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4(+) T cells in melanomas
por: Du, Xuedan, et al.
Publicado: (2022)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Comprehensive Characterization of Stage IIIA Non-Small Cell Lung Carcinoma
por: Singh, Neetu, et al.
Publicado: (2020)

Extremely Potent Block of Bacterial Voltage-Gated Sodium Channels by µ-Conotoxin PIIIA
por: Finol-Urdaneta, Rocio K., et al.
Publicado: (2019)

Usage of Cell-Free Protein Synthesis in Post-Translational Modification of μ-Conopeptide PIIIA
por: Liu, Yanli, et al.
Publicado: (2023)

Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma
por: Wang, Bin, et al.
Publicado: (2022)

Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer
por: Chen, Chih-Yu, et al.
Publicado: (2020)

Commentary: A new PORT in the stage IIIA N2 non–small cell lung cancer storm
por: Ashbrook, Matthew J., et al.
Publicado: (2021)

The prognosis of clinical stage IIIa non‐small cell lung cancer in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2023)

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
por: Fu, Sha, et al.
Publicado: (2015)

Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer
por: Lei, Tao, et al.
Publicado: (2016)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer
por: Kang, Min Kyu, et al.
Publicado: (2006)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Mechanism of μ-Conotoxin PIIIA Binding to the Voltage-Gated Na(+) Channel Na(V)1.4
por: Chen, Rong, et al.
Publicado: (2014)

Role of the disulfide bond on the structure and activity of μ-conotoxin PIIIA in the inhibition of Na(V)1.4
por: Xu, Xiaoxiao, et al.
Publicado: (2019)

The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer
por: Lee, Jin Gu, et al.
Publicado: (2008)

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer
por: Jing, Xuquan, et al.
Publicado: (2016)

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

Treatment-Related Predictive and Prognostic Factors in Trimodality Approach in Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Jeremić, Branislav, et al.
Publicado: (2018)

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study
por: Wang, Suyu, et al.
Publicado: (2021)

Value of postoperative radiotherapy for stage IIIa-N2 non-small cell lung cancer: an analysis based on SEER database
por: Yang, Ran, et al.
Publicado: (2022)

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy
por: Qu, Chenghao, et al.
Publicado: (2022)

Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer
por: Wang, Huan-Huan, et al.
Publicado: (2017)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Bone metastasis after stage IIIA non-small cell lung cancer: risks and prognosis
por: de Bessa, Camila Martins, et al.
Publicado: (2022)

Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non‐small cell lung cancer
por: Miao, Jinbai, et al.
Publicado: (2015)

The Prognosis According to Patterns of Mediastinal Lymph Node Metastasis in Pathologic Stage IIIA/N2 Non-Small Cell Lung Cancer
por: Kim, Do Wan, et al.
Publicado: (2014)

Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
por: Feng, Wen, et al.
Publicado: (2016)

Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer
por: Kang, Jingjing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1j3a2irc3a2734eetfjkasas48